atorvastatin has been researched along with tyrosine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Cheung, R; Mutus, B; Tannous, M; Vignini, A | 1 |
| Mitka, M | 1 |
| Dixon, JL; Katwa, LC; Lee, DL; Reddy, HK; Sturek, M; Voelker, DJ; Wamhoff, BR | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Pearce, GL; Penn, MS; Shishehbor, MH; Sprecher, DL; Vita, JA | 1 |
| Böhm, M; Fries, R | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Hazen, SL; Penn, MS; Shishehbor, MH; Sprecher, DL | 1 |
| Beckman, JA; Chui, D; Creager, MA; Garrett, LA; Hurley, S; Liao, JK; Mitra, D | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Brown, BG | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Blazing, M; Cannon, CP; Gersh, B; McLean, DS; Ravid, S; Shui, A | 1 |
| Acar, G; Nacar, AB; Sökmen, G; Tuncer, C | 1 |
| Devaraj, S; Jialal, I; Siegel, D; Singh, U | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Chen, Z; Dixon, RA; Ganjehei, L; Haidari, M; Mortazavi, A; Vanderslice, P; Warier, N; Zhang, W | 1 |
| de Oliveira, CV; Funck, VR; Furian, AF; Grigoletto, J; Oliveira, MS; Pereira, LM; Rambo, LM; Ribeiro, LR; Royes, LF | 1 |
| Han, L; Li, MG; Ye, P | 1 |
| Choudhury, S; Gupta, P; Harikumar, SK; Kannan, K; Mishra, SK; Pillai, AH; Sarath, TS; Sarkar, SN; Waghe, P | 1 |
| Takaguri, A | 1 |
| Anghel, R; Forsea, L; Gales, L; Georgescu, M; Mitrea, D; Mitrica, R; Serbanescu, L; Stanculescu, I; Stefanica, I; Trifanescu, O | 1 |
3 review(s) available for atorvastatin and tyrosine
| Article | Year |
|---|---|
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
[Elucidation of a New Mechanism of Onset of Insulin Resistance: Effects of Statins and Tumor Necrosis Factor-α on Insulin Signal Transduction].
Topics: Adipocytes; AMP-Activated Protein Kinases; Animals; Atorvastatin; Diabetes Mellitus; Dual-Specificity Phosphatases; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Mice; Mitogen-Activated Protein Kinase Phosphatases; Phosphorylation; rho-Associated Kinases; rhoA GTP-Binding Protein; Serine; Signal Transduction; Tumor Necrosis Factor-alpha; Tyrosine | 2018 |
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihypertensive Agents; Antimalarials; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Mebendazole; Metformin; Mevalonic Acid; Propranolol; Protein Kinases; Proto-Oncogene Proteins B-raf; Receptors, Adrenergic, beta-2; Tyrosine | 2022 |
7 trial(s) available for atorvastatin and tyrosine
| Article | Year |
|---|---|
Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Induction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidation-Reduction; Pyrroles; Treatment Outcome; Triglycerides; Tyrosine; Vasodilation | 1999 |
Statins promote potent systemic antioxidant effects through specific inflammatory pathways.
Topics: Antioxidants; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Reactive Oxygen Species; Signal Transduction; Statistics, Nonparametric; Tyrosine | 2003 |
Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
Topics: Adult; Atorvastatin; Brachial Artery; Cholesterol; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; RNA, Messenger; Skin; Smoking; Tyrosine; Ultrasonography; Vasodilation | 2004 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Atrial Fibrillation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Inflammation; Male; Matrix Metalloproteinase 9; Metabolic Syndrome; Middle Aged; Monocytes; NF-kappa B; Oxidative Stress; Polyethylene; Pyrroles; Superoxides; Tyrosine | 2008 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
11 other study(ies) available for atorvastatin and tyrosine
| Article | Year |
|---|---|
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Fast, aggressive treatment for myocardial infarction urged.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Stents; Tirofiban; Tyrosine | 2000 |
Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Calcium; Calcium Signaling; Coronary Artery Disease; Diabetes Complications; Diet; Disease Models, Animal; Endothelin-1; Endothelins; Heptanoic Acids; Hyperlipidemias; Male; Phosphorylation; Pyrroles; Receptor, Endothelin A; Receptors, Endothelin; Swine; Tyrosine | 2003 |
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tyrosine | 2003 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
Efficient tirofiban infusion resulting in resolution of intracoronary thrombus.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Electrocardiography; Fibrinolytic Agents; Heptanoic Acids; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Atorvastatin preserves the integrity of endothelial adherens junctions by inhibiting vascular endothelial cadherin tyrosine phosphorylation.
Topics: Adherens Junctions; Atorvastatin; Cadherins; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Interleukin-1beta; Lipopolysaccharides; Myosin Light Chains; Phosphorylation; Pyrroles; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Tyrosine | 2012 |
Atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex.
Topics: Animals; Atorvastatin; Cerebral Cortex; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide; Oxidation-Reduction; Pyrroles; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Superoxide Dismutase; Tyrosine | 2013 |
[The effect of PPARalpha signal channel on atorvastatin inhibiting MMP-9 expression in aging myocytes].
Topics: Aging; Animals; Atorvastatin; Cells, Cultured; Heptanoic Acids; Matrix Metalloproteinase 9; Muscle Cells; Oxazoles; PPAR alpha; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Tyrosine | 2013 |
Atorvastatin ameliorates arsenic-induced hypertension and enhancement of vascular redox signaling in rats.
Topics: Animals; Aorta, Thoracic; Arsenites; Atorvastatin; Catalase; Cholesterol; Glutathione Peroxidase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Random Allocation; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sodium Compounds; Superoxide Dismutase; Tyrosine | 2014 |